Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre study.

    Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
    Summary
    EudraCT number
    2012-004779-38
    Trial protocol
    FI   GB   ES   PT   SK   BE   DE   CZ   HU   PL   SE   NO   DK   GR   FR  
    Global end of trial date
    10 Sep 2014

    Results information
    Results version number
    v1(current)
    This version publication date
    06 Jul 2016
    First version publication date
    06 Jul 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CL3-16257-102
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Institut de Recherches Internationales Servier
    Sponsor organisation address
    50 rue Carnot, Suresnes, France,
    Public contact
    ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 155 72 43 66, clinicaltrials@servier.com
    Scientific contact
    ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 155 72 43 66, clinicaltrials@servier.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    10 Sep 2014
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    10 Sep 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    10 Sep 2014
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To evaluate the effect of ivabradine treatment for 18 months on atherosclerotic disease progression as assessed using coronary Intravascular Ultrasound (IVUS) in patients with coronary artery disease (CAD).
    Protection of trial subjects
    This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient. Care was taken to ensure that the plaque burden in the target artery was not too high as to significantly increase the risk incurred by the imaging procedures. The decision to prematurely discontinue the study (issued in agreement with the Study Executive Committee and the Data Monitoring Committee) was triggered by the results of the SIGNIFY study which used the same therapeutic schemas as the present study (up-titration up to 10 mg bid) and failed to demonstrate the efficacy of ivabradine in preventing cardiovascular events in patients with CAD and without clinical heart failure.
    Background therapy
    Treatment with optimal doses of lipid lowering therapies and recommended treatment for CAD.
    Evidence for comparator
    -
    Actual start date of recruitment
    24 Apr 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 64
    Country: Number of subjects enrolled
    Portugal: 4
    Country: Number of subjects enrolled
    Slovakia: 14
    Country: Number of subjects enrolled
    United Kingdom: 1
    Country: Number of subjects enrolled
    Belgium: 5
    Country: Number of subjects enrolled
    Czech Republic: 9
    Country: Number of subjects enrolled
    Finland: 1
    Country: Number of subjects enrolled
    Spain: 11
    Country: Number of subjects enrolled
    France: 4
    Country: Number of subjects enrolled
    Germany: 5
    Country: Number of subjects enrolled
    Hungary: 40
    Country: Number of subjects enrolled
    Italy: 38
    Country: Number of subjects enrolled
    Australia: 16
    Country: Number of subjects enrolled
    Romania: 1
    Country: Number of subjects enrolled
    Korea, Republic of: 57
    Country: Number of subjects enrolled
    Malaysia: 4
    Country: Number of subjects enrolled
    Russian Federation: 60
    Country: Number of subjects enrolled
    Taiwan: 26
    Worldwide total number of subjects
    360
    EEA total number of subjects
    197
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    251
    From 65 to 84 years
    108
    85 years and over
    1

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Patients were male or female (non-childbearing potential) aged 18 years or older, in sinus rhythm and HR ≥ 70 bpm, with coronary artery disease who had a clinical indication for coronary angiography.

    Pre-assignment
    Screening details
    Patients had to show a sufficient level of atheroma burden (at least one stenosis > 20%) or a prior history of percutaneous coronary intervention without increasing significantly the risk incurred by intravascular ultrasound or optical coherence tomography procedures (no stenosis > 50% in the target artery).

    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator
    Blinding implementation details
    Identical tablets and packaging for the two treatment arms.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Ivabradine
    Arm description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.
    Arm type
    Experimental

    Investigational medicinal product name
    Ivabradine
    Investigational medicinal product code
    16257
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    In patients < 75 years, starting dose was 7.5 mg twice daily then maintained at 7.5 mg or up-titrated to 10 mg or down-titrated to 5 mg. In elderly patients (≥ 75 years), starting dose was 5 mg twice daily with possibly up-titration to 7.5 mg and then 10 mg.

    Arm title
    placebo
    Arm description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.
    Arm type
    Placebo

    Investigational medicinal product name
    placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo tablets matching those of ivabradine with the same titration protocol as described in the ivabradine arm.

    Number of subjects in period 1
    Ivabradine placebo
    Started
    178
    182
    Completed
    0
    0
    Not completed
    178
    182
         Consent withdrawn by subject
    8
    5
         Adverse event, non-fatal
    3
    -
         premature study termination
    167
    177

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Ivabradine
    Reporting group description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.

    Reporting group title
    placebo
    Reporting group description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.

    Reporting group values
    Ivabradine placebo Total
    Number of subjects
    178 182 360
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    132 119 251
        From 65-84 years
    45 63 108
        85 years and over
    1 0 1
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    59.4 ( 8.9 ) 59.8 ( 9.7 ) -
    Gender categorical
    Units: Subjects
        Female
    50 55 105
        Male
    128 127 255

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Ivabradine
    Reporting group description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.

    Reporting group title
    placebo
    Reporting group description
    18 months of treatment with visits at 1, 2, 3, 6, 9, 12, 15, 18 months and a second IVUS at 18 months.

    Subject analysis set title
    Randomised Set
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    All included and randomised patients

    Primary: Coronary Percent Atheroma Volume

    Close Top of page
    End point title
    Coronary Percent Atheroma Volume [1]
    End point description
    Following the premature termination of the study, the post-baseline coronary imaging measurements were not performed.
    End point type
    Primary
    End point timeframe
    Change in coronary Percent Atheroma Volume from baseline to the study end for all anatomically comparable slices in a 30-mm segment of the target coronary artery.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Post-baseline primary endpoint was not assessed. No statistical analysis was performed.
    End point values
    Ivabradine placebo
    Number of subjects analysed
    0 [2]
    0 [3]
    Units: not available
    Notes
    [2] - post-baseline primary endpoint not assessed
    [3] - post-baseline primary endpoint not assessed
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All adverse events which occurred during the treatment period are presented here.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.0
    Reporting groups
    Reporting group title
    placebo
    Reporting group description
    -

    Reporting group title
    Ivabradine
    Reporting group description
    -

    Serious adverse events
    placebo Ivabradine
    Total subjects affected by serious adverse events
         subjects affected / exposed
    25 / 181 (13.81%)
    22 / 176 (12.50%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    2 / 181 (1.10%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypertensive crisis
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral ischaemia
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Surgical and medical procedures
    Abdominal hernia repair
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic aneurysm repair
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac rehabilitation therapy
         subjects affected / exposed
    2 / 181 (1.10%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary revascularisation
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Percutaneous coronary intervention
         subjects affected / exposed
    3 / 181 (1.66%)
    2 / 176 (1.14%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral artery angioplasty
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Metaplasia
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Social circumstances
    Activities of daily living impaired
         subjects affected / exposed
    1 / 181 (0.55%)
    3 / 176 (1.70%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Impaired driving ability
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory failure
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Arteriogram coronary
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigation
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Ankle fracture
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haematoma
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Angina pectoris
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 181 (0.55%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bradycardia
         subjects affected / exposed
    0 / 181 (0.00%)
    3 / 176 (1.70%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    1 / 181 (0.55%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac ventricular thrombosis
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Left ventricular dysfunction
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mitral valve incompetence
         subjects affected / exposed
    1 / 181 (0.55%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Right ventricular failure
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ventricular extrasystoles
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral artery stenosis
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Age-related macular degeneration
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Photopsia
         subjects affected / exposed
    1 / 181 (0.55%)
    2 / 176 (1.14%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinal detachment
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinopathy
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinopathy proliferative
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vision blurred
         subjects affected / exposed
    1 / 181 (0.55%)
    2 / 176 (1.14%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vitreous haemorrhage
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Enteritis
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastric ulcer haemorrhage
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic congestion
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal failure chronic
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Gouty arthritis
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spondylolisthesis
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tooth abscess
         subjects affected / exposed
    0 / 181 (0.00%)
    1 / 176 (0.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Type 2 diabetes mellitus
         subjects affected / exposed
    1 / 181 (0.55%)
    0 / 176 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 1%
    Non-serious adverse events
    placebo Ivabradine
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    66 / 181 (36.46%)
    80 / 176 (45.45%)
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    4 / 181 (2.21%)
    3 / 176 (1.70%)
         occurrences all number
    4
    3
    Aspartate aminotransferase increased
         subjects affected / exposed
    3 / 181 (1.66%)
    2 / 176 (1.14%)
         occurrences all number
    3
    2
    Blood cholesterol increased
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Blood triglycerides increased
         subjects affected / exposed
    1 / 181 (0.55%)
    3 / 176 (1.70%)
         occurrences all number
    1
    3
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    3 / 181 (1.66%)
    3 / 176 (1.70%)
         occurrences all number
    3
    3
    Heart rate decreased
         subjects affected / exposed
    1 / 181 (0.55%)
    9 / 176 (5.11%)
         occurrences all number
    1
    10
    High density lipoprotein decreased
         subjects affected / exposed
    0 / 181 (0.00%)
    3 / 176 (1.70%)
         occurrences all number
    0
    3
    Low density lipoprotein increased
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Vascular disorders
    Hypertension
         subjects affected / exposed
    4 / 181 (2.21%)
    9 / 176 (5.11%)
         occurrences all number
    4
    10
    Hypotension
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Orthostatic hypotension
         subjects affected / exposed
    4 / 181 (2.21%)
    1 / 176 (0.57%)
         occurrences all number
    4
    1
    Cardiac disorders
    Angina pectoris
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Bradycardia
         subjects affected / exposed
    1 / 181 (0.55%)
    3 / 176 (1.70%)
         occurrences all number
    1
    3
    Bundle branch block right
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences all number
    2
    0
    Sinus bradycardia
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Sinus tachycardia
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences all number
    2
    0
    Supraventricular extrasystoles
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Ventricular extrasystoles
         subjects affected / exposed
    1 / 181 (0.55%)
    4 / 176 (2.27%)
         occurrences all number
    1
    4
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    6 / 181 (3.31%)
    3 / 176 (1.70%)
         occurrences all number
    6
    4
    Dizziness postural
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Headache
         subjects affected / exposed
    3 / 181 (1.66%)
    3 / 176 (1.70%)
         occurrences all number
    3
    4
    General disorders and administration site conditions
    Chest discomfort
         subjects affected / exposed
    1 / 181 (0.55%)
    5 / 176 (2.84%)
         occurrences all number
    1
    5
    Chest pain
         subjects affected / exposed
    4 / 181 (2.21%)
    3 / 176 (1.70%)
         occurrences all number
    4
    3
    Local swelling
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences all number
    2
    0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 181 (0.55%)
    2 / 176 (1.14%)
         occurrences all number
    1
    3
    Oedema peripheral
         subjects affected / exposed
    2 / 181 (1.10%)
    4 / 176 (2.27%)
         occurrences all number
    2
    4
    Eye disorders
    Photopsia
         subjects affected / exposed
    0 / 181 (0.00%)
    13 / 176 (7.39%)
         occurrences all number
    0
    14
    Vision blurred
         subjects affected / exposed
    2 / 181 (1.10%)
    8 / 176 (4.55%)
         occurrences all number
    2
    9
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    0 / 181 (0.00%)
    3 / 176 (1.70%)
         occurrences all number
    0
    4
    Constipation
         subjects affected / exposed
    3 / 181 (1.66%)
    2 / 176 (1.14%)
         occurrences all number
    3
    2
    Diarrhoea
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Dyspepsia
         subjects affected / exposed
    2 / 181 (1.10%)
    1 / 176 (0.57%)
         occurrences all number
    2
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Nausea
         subjects affected / exposed
    2 / 181 (1.10%)
    2 / 176 (1.14%)
         occurrences all number
    2
    2
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    4 / 181 (2.21%)
    0 / 176 (0.00%)
         occurrences all number
    4
    0
    Dyspnoea
         subjects affected / exposed
    1 / 181 (0.55%)
    4 / 176 (2.27%)
         occurrences all number
    1
    4
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Pruritus generalised
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences all number
    2
    0
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    1 / 181 (0.55%)
    2 / 176 (1.14%)
         occurrences all number
    1
    2
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    2
    Gastroenteritis
         subjects affected / exposed
    0 / 181 (0.00%)
    2 / 176 (1.14%)
         occurrences all number
    0
    3
    Nasopharyngitis
         subjects affected / exposed
    6 / 181 (3.31%)
    4 / 176 (2.27%)
         occurrences all number
    6
    4
    Metabolism and nutrition disorders
    Hypercholesterolaemia
         subjects affected / exposed
    2 / 181 (1.10%)
    0 / 176 (0.00%)
         occurrences all number
    2
    0
    Hypertriglyceridaemia
         subjects affected / exposed
    0 / 181 (0.00%)
    3 / 176 (1.70%)
         occurrences all number
    0
    3
    Type 2 diabetes mellitus
         subjects affected / exposed
    2 / 181 (1.10%)
    1 / 176 (0.57%)
         occurrences all number
    2
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    04 Jun 2013
    The following points were added: treatment with strong cytochrome P450 3A4 inhibitor as non-inclusion criteria, a centralised analysis of the blood samples for lipid profile, ­an optional genomic analysis. The assessment of biomarkers pertinent to the atherosclerotic process was updated.
    04 Dec 2013
    A Data Monitoring Committee (DMC) was constituted. History of persistent atrial fibrillation was added as non-selection criteria. During the coronary angiography procedure for entry in the study, the use of 3-lead ECG (if no 12-lead ECG available) as well as the use ­of an equivalent treatment to nitroglycerin were authorised. ­

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The median treatment duration was 4.5 months with a maximum of 13.5 months. Thus, the M18 visit (and second IVUS examination) was not attained by any patient, so no estimation of treatment effect on the primary criterion was possible.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:07:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA